Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2147 - Identification of novel CRC pathway genes in familial CRC


10 Oct 2016


Poster display


Mei Sim Lung


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


M.S. Lung1, A. Trainer2, I. Campbell1

Author affiliations

  • 1 Research, Peter MacCallum Cancer Centre, 3002 - East Melbourne/AU
  • 2 Familial Cancer Centre, Peter MacCallum Cancer Centre, 3002 - East Melbourne/AU


Abstract 2147


The Wnt, DNA repair and bone morphogenetic protein (BMP) pathways are implicated in development of familial colorectal cancer (CRC) through inherited mutations in genes such as APC, MLH1, MSH2, MSH6, PMS2, POLE, POLD1, MUTYH, SMAD4 and BMPR1A. We hypothesised that mutations in other genes within these pathways may predispose to unexplained familial colorectal cancer, and sought rare potentially deleterious variants in genes within these pathways in a cohort of familial and/or young-onset CRC cases.


We performed whole exome sequencing on constitutional DNA from 51 individuals with unexplained familial or young-onset (


We identified a rare LoF variant in each of the following genes: WNT10 and LRRFIP2 from the Wnt pathway, APLF, DMC1, ERCC3, MUS81, USP28 and XRCC6BP1 from the DNA repair pathway, and GDF2 from the BMP pathway. Each LoF variant was seen once in our cohort. The LoF variants in WNT10 and USP28 were seen in the same individual, whereas the other variants occurred in distinct individuals.


Whole exome sequencing identified rare LoF variants in genes within CRC pathways in familial and/or young onset CRC cases. Validation in a larger cohort of familial and/or young onset CRC cases is required to determine the association of these genes with CRC development. Targeted sequencing of these genes in a cohort of 300-400 cases of familial and/or young onset CRC is underway.

Clinical trial identification

Legal entity responsible for the study

Peter MacCallum Cancer Centre


University of Melbourne Cancer Council Victoria


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings